Primary Biliary Cirrhosis Clinical Trial
Official title:
Phase III Trial of Tetrathiomolybdate (TM) in Primary Biliary Cirrhosis
The University of Michigan is conducting a study investigating a potential new treatment aimed at slowing/halting progression of primary biliary cirrhosis. This will be a 2 arm double blind study in which half of the patients will be randomly selected to receive a placebo (capsule with no active ingredient) and half will receive the new treatment drug, tetrathiomolybdate. Neither the patient nor the treating physician will know which arm the patient is in. The length of the study for each patient is 24 months of drug therapy. Lab draws will be necessary weekly for the first 6 weeks of the study, followed by every other week for 3 weeks, and then monthly for the remainder of the 2 year period. In addition, intermittent history and physicals and urine samples will also be necessary. There is no cost to you for any experimental treatment. All patients in both arms will continue on ursodiol and receive standard of care treatment
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04526665 -
Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)
|
Phase 3 | |
Recruiting |
NCT02931513 -
sCD163 in PBC Patients - Assessment of Treatment Response
|
||
Active, not recruiting |
NCT02924701 -
sCD163 in PBC Patients - Assessment of Disease Severity and Prognosis
|
||
Completed |
NCT02659696 -
Nalfurafine Hydrochloride for Pruritus in Patients With Primary Biliary Cholangitis
|
||
Completed |
NCT02078882 -
Study of Abatacept (Orencia) to Treat Primary Biliary Cirrhosis
|
Phase 4 | |
Completed |
NCT01389973 -
A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid
|
Phase 2 | |
Completed |
NCT01603199 -
High-protein High-fiber Diet in Patients With Primary Biliary Cirrhosis
|
N/A | |
Completed |
NCT01857284 -
Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary Cirrhosis
|
Phase 3 | |
Completed |
NCT05374200 -
Mind-body Wellness Intervention in Primary Biliary Cholangitis (PBC)
|
N/A | |
Recruiting |
NCT02937012 -
Use of Bezafibrate in Patients With Primary Biliary Cirrhosis to Archive Complete Biochemical Response in Non-responders
|
Phase 3 | |
Completed |
NCT02376335 -
B-Cell Depleting Therapy (Rituximab) as a Treatment for Fatigue in Primary Biliary Cirrhosis
|
Phase 2 | |
Recruiting |
NCT01662973 -
Umbilical Cord Mesenchymal Stem Cells for Patients With Primary Biliary Cirrhosis
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04751188 -
A Study to Assess Efficacy and Safety of Bezafibrate in Patients With Primary Biliary Cholangitis
|
Phase 3 | |
Recruiting |
NCT04514965 -
Bezafibrate in Patients With Primary Biliary Cholangitis (PBC)
|
||
Recruiting |
NCT03668145 -
Mesenchymal Stem Cell Transplantation for Refractory Primary Biliary Cholangitis
|
N/A | |
Completed |
NCT02955602 -
Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC)
|
Phase 2 | |
Completed |
NCT02557360 -
Effectiveness of S-adenosyl-L-methionine in Patients With Primary Biliary Cirrhosis
|
Phase 4 | |
Recruiting |
NCT01440309 -
Efficacy and Safety Study of Allogenic Mesenchymal Stem Cells for Patients With Refractory Primary Biliary Cirrhosis
|
Phase 1 | |
Completed |
NCT01249092 -
Pentoxifylline for Primary Biliary Cirrhosis
|
Phase 2 | |
Completed |
NCT01510860 -
Ursofalk Tablets (500 mg) Versus Ursofalk Capsules (250 mg) in the Treatment of Primary Biliary Cirrhosis
|
Phase 4 |